Industry Experts Announced for BIO’s Investor Conference

Washington, D.C. (February 14, 2002) - The Biotechnology Industry Organization (BIO) today announced the names of industry leaders who will participate in the opening and closing plenary sessions of the fourth annual CEO & Investor Conference, Feb. 20-22 at the Waldorf-Astoria Hotel in New York.


WHAT: “Building Shareholder Value Through Merger & acquisition”
WHEN: Wednesday, Feb. 20, 8:00 - 9:20 a.m.
WHO: Panelists
David Mott, CEO of MedImmune, Inc.
C. Boyd Clarke, CEO of Aviron
Kevin Starr, COO of Millennium Pharmaceuticals, Inc.
Vaughn Kailian, vice chairman of Millennium Pharmaceuticals, Inc., and former CEO of COR Therapeutics, Inc.
Joshua Boger, CEO of Vertex Pharmaceuticals, Inc.
Stuart Collinson, former CEO of Aurora Biosciences Corporation
Tracy Lefteroff, global life sciences director for PriceWaterhouseCoopers, LLP
Eric Roberts, managing director of Lehman Brothers
WHERE: Waldorf-Astoria Hotel, Grand Ballroom


WHAT: “Managing through Biotech’s Binary Events”
WHEN: Friday, Feb. 22, 12:00 - 1:30 p.m.
WHO: Analysts and Fund Managers
Denis Purcell, senior managing partner of Perseus/Soros BioPharmaceutical Fund LLC
Steve Delco, analyst for Fortis Bank
Mary Ann Gray, health-care analyst for the Federated Kaufmann Fund
Bill Slattery, partner and biotechnology analyst for Deerfield Partners
CEO Panelists
Vaughn Kailian, vice chairman of Millennium Pharmaceuticals, Inc., and former CEO of COR Therapeutics, Inc.
Raymond Warrell, MD, CEO of Genta, Inc.
Richard Pops, CEO of Alkermes, Inc.
Vivian Lee, managing director of Roberts Mitani Aqua Partners
WHERE: Waldorf-Astoria Hotel, Grand Ballroom

For more information on the CEO & Investor Conference 2002, please visit Press registration is complimentary for credentialed members of the news media. Advance press registration closes on Feb. 14. Press releases, conference updates and registration information are posted in the “Media” section of the conference Web site. Contact Carrie Housman at BIO (202-962-9200) with any questions.

BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers and related organizations in all 50 U.S. states and 33 other nations. BIO members are involved in the research and development of health-care, agricultural, industrial and environmental biotechnology products. For more information, please visit

# # #